Ranibizumab

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ranibizumab

CAS No. : 347396-82-1

MCE 国际站：Ranibizumab

产品活性：Ranibizumab (RG-6321) 是一种人源化的抗 VEGF 单克隆抗体片段，能够识别所有 VEGF-A 亚型 (VEGF110，VEGF121，以及 VEGF165)。动物模型中，Ranibizumab 减缓视力丧失，并用于老年黄斑变性 (AMD) 的研究。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：VEGFR

In Vitro: Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment (IgG antigen-binding fragment (Fab-Y0317). Ranibizumab (0.0625-0.25 mg/ml; 72 hours) results in increased necrosis and apoptosis at in rat retinal cell cultures.

In Vivo: Studies in monkeys demonstrates that after a single intravitreal administration, Ranibizumab can distribute rapidly to the retina (6–24?h). Ranibizumab can rapidly penetrate through the retina to reach the choroid, just 1?h after intravitreal administration in rabbits.
In a study comparing the pharmacokinetics of 0.5?mg of intravitreal Ranibizumab with 1.25?mg of intravitreal Bevacizumab (HY-P9906) in the rabbit, the vitreous half-life of Ranibizumab is 2.88 days, shorter than the Bevacizumab half-life of 4.32 days. Peak concentrations in the aqueous humor of the treated eye at 3 days following treatment are 37.7?μg/ml for Bevacizumab?and 17.9?μg/ml for Ranibizumab, respectively.

相关产品：Sorafenib  |  Lenvatinib  |  Sunitinib  |  Regorafenib  |  Nintedanib  |  Bevacizumab  |  Semaxinib  |  Cabozantinib  |  Ponatinib  |  Axitinib  |  Midostaurin  |  Chloramphenicol  |  Pazopanib  |  PD173074  |  5Z-7-Oxozeaenol  |  Linifanib  |  Tanshinone IIA  |  Vandetanib  |  Foretinib  |  SU 5402  |  Fruquintinib  |  SPHINX31  |  Ripretinib  |  E3330  |  Dovitinib  |  GW806742X  |  Sitravatinib

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds